AKT1 and hepatocellular carcinoma: Co-expression of SET and Akt predicted shorter post-operative recurrence-free survival in patients with HCC, and the combination of a novel SET antagonist, N4-(3-ethynylphenyl)-6,7-dimethoxy-N2-(4-phenoxyphenyl) quinazoline-2,4-diamine (EMQA developed by Hung et al. 2016), and sorafenib acted synergistically in terms of enhancing survival from HCC (Hung et al. 2016).